Dusa Pharma (Dusa)

[surf1944]

Leading Investigators Highlight Advances in Photodynamic Therapy at the American Academy of Dermatology Annual Meeting
Wednesday February 6, 6:00 am ET

First-Line Treatment for Patients at Risk for Skin Cancer Evaluated for Potential Effectiveness for Wide Array of Dermatologic Needs

WILMINGTON, MASSACHUSETTS--(MARKET WIRE)--Feb 6, 2008 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) -

Photodynamic Therapy (PDT) was featured as a key topic at the 66th Annual American Academy of Dermatology (AAD) Meeting in San Antonio, Texas. More than 25 presentations and posters by prominent investigators addressed PDT, focusing on the therapy's benefits and clinical developments, including the FDA-approved use of aminolevulinic acid (ALA) PDT for the treatment of mild to moderate actinic keratoses (AKs) of the face or scalp, as well as investigational uses for skin cancer, acne and numerous other skin conditions.

http://biz.yahoo.com/iw/080206/0358052.html